Pre-extensively drug-resistant tuberculosis spondylodiscitis in an immunocompetent patient: a case report

Fellous, S.; Rkain, Hanan; Tahiri, Latifa; Bouraqadi, A.; Nassar, Ittimad; Allali, F.

doi:10.11604/pamj.2020.36.165.21689

Cited by 1 publication

(1 citation statement)

References 9 publications

(8 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This is mostly due to unavailability of potent drugs and the lengthy and complicated treatment course which deteriorates the overall treatment outcomes. 2–5 Developing new, safe, high-efficiency anti-TB drugs is the mainstay to cope with the seriousness of drug resistance.…”

Section: Introductionmentioning

confidence: 99%

In vitro and Intracellular Antibacterial Activity of Sudapyridine (WX-081) Against Tuberculosis

Xiao¹,

Yu²,

Shang³

et al. 2023

IDR

View full text Add to dashboard Cite

Background Sudapyridine (WX-081) has exhibited equivalent efficacy than its counterpart parent drug bedaquiline (BDQ) but better safety profile against Mycobacterium tuberculosis ( Mtb ). Our study was aimed to evaluate in vitro activity of WX-081 against the clinical isolates of Mtb with different drug-resistance profiles and the intracellular bactericidal activity against the reference strain. Methods The minimum inhibitory concentrations (MICs) of WX-081 and BDQ were tested against 114 Mtb clinical isolates. The intracellular activity of WX-081 and BDQ against the Mtb reference strain H37Rv in THP-1 cells was also evaluated in parallel. Results The MICs for WX-081 of the enrolled isolates ranged from 0.0156 μg/mL to 1 μg/mL. The MIC 50 and MIC 90 of WX-081 were, respectively, 0.25 μg/mL and 0.5 μg/mL, with 95.6% of the enrolled strains having MICs ≤0.25 μg/mL. For a given strain, the MIC value of WX-081 was generally equivalent to or 2-fold than MIC of BDQ. The intracellular bacterial killing was acquired with the tested drug concentrations that were presumed attainable during clinical usage. Conclusion WX-081 exhibited potent efficacy against the clinical isolates in vitro. The intracellular killing effect of sudapyridine against the reference strain supports its potential efficacy in treating TB patients.

show abstract

Section: Introductionmentioning

confidence: 99%